South Korea
· Delayed Price · Currency is KRW Hanmi Pharm. Statistics
Total Valuation
Hanmi Pharm. has a market cap or net worth of KRW 5.40 trillion. The enterprise value is 5.77 trillion.
| Market Cap | 5.40T |
| Enterprise Value | 5.77T |
Important Dates
The next estimated earnings date is Friday, February 13, 2026.
| Earnings Date | Feb 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Hanmi Pharm. has 12.68 million shares outstanding. The number of shares has decreased by -0.03% in one year.
| Current Share Class | 12.68M |
| Shares Outstanding | 12.68M |
| Shares Change (YoY) | -0.03% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | 7.81% |
| Owned by Institutions (%) | 20.15% |
| Float | 6.22M |
Valuation Ratios
The trailing PE ratio is 46.37 and the forward PE ratio is 31.42. Hanmi Pharm.'s PEG ratio is 1.48.
| PE Ratio | 46.37 |
| Forward PE | 31.42 |
| PS Ratio | 3.68 |
| PB Ratio | 4.01 |
| P/TBV Ratio | 4.74 |
| P/FCF Ratio | 42.24 |
| P/OCF Ratio | 31.17 |
| PEG Ratio | 1.48 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.65, with an EV/FCF ratio of 45.15.
| EV / Earnings | 49.57 |
| EV / Sales | 3.94 |
| EV / EBITDA | 19.65 |
| EV / EBIT | 29.47 |
| EV / FCF | 45.15 |
Financial Position
The company has a current ratio of 1.40, with a Debt / Equity ratio of 0.32.
| Current Ratio | 1.40 |
| Quick Ratio | 0.82 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | 1.48 |
| Debt / FCF | 3.41 |
| Interest Coverage | 10.45 |
Financial Efficiency
Return on equity (ROE) is 9.90% and return on invested capital (ROIC) is 6.94%.
| Return on Equity (ROE) | 9.90% |
| Return on Assets (ROA) | 6.10% |
| Return on Invested Capital (ROIC) | 6.94% |
| Return on Capital Employed (ROCE) | 13.47% |
| Revenue Per Employee | 610.91M |
| Profits Per Employee | 48.54M |
| Employee Count | 2,400 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 2.15 |
Taxes
In the past 12 months, Hanmi Pharm. has paid 28.80 billion in taxes.
| Income Tax | 28.80B |
| Effective Tax Rate | 18.33% |
Stock Price Statistics
The stock price has increased by +54.95% in the last 52 weeks. The beta is 0.48, so Hanmi Pharm.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | +54.95% |
| 50-Day Moving Average | 409,360.00 |
| 200-Day Moving Average | 308,557.50 |
| Relative Strength Index (RSI) | 46.67 |
| Average Volume (20 Days) | 124,886 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Hanmi Pharm. had revenue of KRW 1.47 trillion and earned 116.48 billion in profits. Earnings per share was 9,186.54.
| Revenue | 1.47T |
| Gross Profit | 809.17B |
| Operating Income | 195.91B |
| Pretax Income | 157.10B |
| Net Income | 116.48B |
| EBITDA | 293.84B |
| EBIT | 195.91B |
| Earnings Per Share (EPS) | 9,186.54 |
Balance Sheet
The company has 225.32 billion in cash and 435.72 billion in debt, giving a net cash position of -210.40 billion or -16,592.52 per share.
| Cash & Cash Equivalents | 225.32B |
| Total Debt | 435.72B |
| Net Cash | -210.40B |
| Net Cash Per Share | -16,592.52 |
| Equity (Book Value) | 1.35T |
| Book Value Per Share | 93,390.87 |
| Working Capital | 234.58B |
Cash Flow
In the last 12 months, operating cash flow was 173.32 billion and capital expenditures -45.44 billion, giving a free cash flow of 127.89 billion.
| Operating Cash Flow | 173.32B |
| Capital Expenditures | -45.44B |
| Free Cash Flow | 127.89B |
| FCF Per Share | 10,085.44 |
Margins
Gross margin is 55.19%, with operating and profit margins of 13.36% and 7.94%.
| Gross Margin | 55.19% |
| Operating Margin | 13.36% |
| Pretax Margin | 10.72% |
| Profit Margin | 7.94% |
| EBITDA Margin | 20.04% |
| EBIT Margin | 13.36% |
| FCF Margin | 8.72% |
Dividends & Yields
This stock pays an annual dividend of 1,250.00, which amounts to a dividend yield of 0.29%.
| Dividend Per Share | 1,250.00 |
| Dividend Yield | 0.29% |
| Dividend Growth (YoY) | 150.00% |
| Years of Dividend Growth | 7 |
| Payout Ratio | 26.49% |
| Buyback Yield | 0.03% |
| Shareholder Yield | 0.32% |
| Earnings Yield | 2.16% |
| FCF Yield | 2.37% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 27, 2023. It was a forward split with a ratio of 1.02.
| Last Split Date | Dec 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.02 |
Scores
Hanmi Pharm. has an Altman Z-Score of 4.81 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.81 |
| Piotroski F-Score | 5 |